AB
DRUG

Amalgamated Bank’s Bright Minds Biosciences DRUG Stock Holding History

Amalgamated Bank’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-159
Closed -$12K – 1965
2025
Q4 		$12K Buy
159
+2
+1% +$134 ﹤0.01% 2332
2025
Q3 		$10K Hold
157
– – ﹤0.01% 2462
2025
Q2 		$4K Buy
+157
New +$4.71K ﹤0.01% 2827

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Amalgamated Bank's DRUG Position: Q1 2026 in Review

Amalgamated Bank sold out of Bright Minds Biosciences (DRUG) in Q1 2026, closing a stake of 159 shares — an estimated $12K sold.

Amalgamated Bank first reported a position in DRUG in Q2 2025 and held it in 3 quarters. The position peaked at $12K in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Amalgamated Bank reported no remaining Bright Minds Biosciences position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 159 Bright Minds Biosciences shares in Q1 2026, an estimated $12K.
  • Amalgamated Bank first reported a position in Bright Minds Biosciences in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Bright Minds Biosciences position peaked at $12K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.